MX2022004341A - Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer. - Google Patents

Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.

Info

Publication number
MX2022004341A
MX2022004341A MX2022004341A MX2022004341A MX2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A
Authority
MX
Mexico
Prior art keywords
phospholipid
methods
flavagline
same
cancer therapy
Prior art date
Application number
MX2022004341A
Other languages
English (en)
Inventor
Jarrod Longcor
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2022004341A publication Critical patent/MX2022004341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan en la presente moléculas de éter de fosfolípido (PLE); además se proporcionan conjugados de fosfolípido-flavaglina ; el conjugado de fosfolípido-flavaglina puede incluir un PLE conjugado a una flavaglina a través de un enlazador; se proporcionan además en la presente métodos para tratar cáncer en un sujeto y métodos para dirigir un fármaco a un tumor o una célula de cáncer en un sujeto.
MX2022004341A 2019-10-10 2020-10-09 Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer. MX2022004341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (1)

Publication Number Publication Date
MX2022004341A true MX2022004341A (es) 2022-08-10

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004341A MX2022004341A (es) 2019-10-10 2020-10-09 Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.

Country Status (11)

Country Link
US (1) US20240325545A1 (es)
EP (1) EP4041718A4 (es)
JP (1) JP2022551495A (es)
KR (1) KR20220080139A (es)
CN (1) CN114761389A (es)
AU (1) AU2020361679A1 (es)
BR (1) BR112022006739B1 (es)
CA (1) CA3154192A1 (es)
IL (1) IL291979A (es)
MX (1) MX2022004341A (es)
WO (1) WO2021072300A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DK1729824T3 (da) * 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
WO2010144788A2 (en) * 2009-06-12 2010-12-16 Cellectar, Inc. Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) * 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
SI3229810T1 (sl) * 2014-11-17 2021-01-29 Cellestar Biosciences, Inc. Analogi fosfolipidnega etra kot vehikli zdravil, usmerjenih proti raku
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
CA3154192A1 (en) 2021-04-15
BR112022006739A2 (pt) 2022-06-28
BR112022006739B1 (pt) 2024-01-23
EP4041718A4 (en) 2023-12-20
JP2022551495A (ja) 2022-12-09
CN114761389A (zh) 2022-07-15
KR20220080139A (ko) 2022-06-14
WO2021072300A1 (en) 2021-04-15
US20240325545A1 (en) 2024-10-03
AU2020361679A1 (en) 2022-04-28
IL291979A (en) 2022-06-01
EP4041718A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
MX2021015887A (es) Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
JOP20210074A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
MX2024000612A (es) Inmunoconjugados y metodos.
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
PH12016501185A1 (en) Compounds to fibrolast growth factor receptor-3 (fgfr3) and therapeutic uses
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
PH12020551715A1 (en) Methods of treating cancer
WO2022093800A3 (en) Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
CL2022003411A1 (es) Conjugados anticuerpo biespecífico-fármaco dirigidos a egfr y muc1 y sus usos
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
MX2023011517A (es) Conjugados de proteina-macromolecula y metodos de uso de los mismos.